Industry News

      Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABCS

      LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in...

      Clarify Health Recognized for Innovation in Patient Recruitment in Clinical Trials

      SAN FRANCISCO--(BUSINESS WIRE)--For the third time this year, Clarify Health, a leading healthcare analytics platform company, is being honored by Frost & Sullivan. This...

      Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022

      HOUSTON--(BUSINESS WIRE)--Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the...

      Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

      VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune...

      Amulet Capital Partners Acquires United Vein & Vascular Centers

      TAMPA, Fla. & GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, today announced...

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.